No black box warning on record for Delstrigo

As of the latest FDA labeling reviewed, Delstrigo (DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Delstrigo medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Severe skin reactions, including Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), have been reported during the postmarketing experience with doravirine-containing regimens. Discontinue DELSTRIGO, and other medications known to be associated with severe skin reactions, immediately if a painful rash with mucosal involvement or a progressive severe rash dev

No black box warning on record for Delstrigo

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Severe skin reactions, including Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), have been reported during the postmarketing experience with doravirine-containing regimens. Discontinue DELSTRIGO, and other medications known to be associated with severe skin reactions, immediately if a painful rash with mucosal involvement or a progressive severe rash dev

Delstrigo Black Box Warning

No black box warning on record for Delstrigo

Other warnings & precautions

Delstrigo Black Box Warning

No black box warning on record for Delstrigo

Other warnings & precautions